In a private admission in 2018, Kenvue, the pharmaceutical company behind Tylenol, acknowledged the potential link between the use of the drug during pregnancy and the development of neurodevelopmental disorders in children.
This revelation was made public in a report by the Daily Caller. Rachel Weinstein, U.S. director of epidemiology for Janssen, the pharmaceutical division of Johnson & Johnson, expressed her growing concern in company documents. "The weight of the evidence is starting to feel heavy to me," she confessed.
As reported by the Daily Caller, these documents were obtained from the law firm Keller Postman LLC, which is spearheading a class-action lawsuit against Kenvue in the Federal District Court for the Southern District of New York. Weinstein revealed that discussions were underway with Rachel Ochs-Ross, a neurologist specializing in the Central Nervous System (CNS). The initial focus of these discussions was the potential benefits of acetaminophen, the active ingredient in Tylenol.
However, the scope has since broadened to include studies on prenatal exposure and neurodevelopmental outcomes. Weinstein also admitted to overlooking a series of papers published in 2016 that could have potentially shed more light on the issue.
In a press conference held on September 22, President Donald Trump drew a connection between autism, childhood vaccines, and the use of Tylenol by pregnant women. "Tylenol is not good. All right, Ill say it; its not good," he declared. He further stated that the U.S. Food and Drug Administration (FDA) strongly advises pregnant women to limit their use of Tylenol unless it is medically necessary. He also cautioned against administering Tylenol to newborns following vaccination. "And you shouldnt give the child a Tylenol every time hes born and he goes and has a shot. You shouldnt give Tylenol to that child."
This revelation about Tylenol's potential risks during pregnancy and its possible link to neurodevelopmental disorders in children has sparked a wave of concern among the public. It underscores the importance of thorough research and transparency in the pharmaceutical industry, particularly when it comes to medications commonly used by pregnant women.
The conservative perspective on this issue emphasizes the need for limited government intervention in the pharmaceutical industry, while also advocating for individual freedom and responsibility. It is crucial for consumers to have access to comprehensive information about the products they use, enabling them to make informed decisions about their health and the health of their children.
The ongoing class-action lawsuit against Kenvue further highlights the need for accountability in the pharmaceutical industry. It serves as a potent reminder that companies must prioritize the well-being of their consumers over profits.
As this case continues to unfold, it will undoubtedly prompt further discussions about the safety of common over-the-counter medications and the potential long-term effects they may have on our health.
Login